Introduction
Approximately 600 000 new cases of head and neck squamous cell carcinoma (HNSCC) are diagnosed worldwide each year (Parkin, 2001; Kamangar et al., 2006; Leemans et al., 2011) . Curative treatment is often achieved in patients presented with early-stage disease through surgery or radiation. Palliative chemotherapy is the standard approach for patients with recurrent/ metastatic disease. The majority, greater than twothirds, of HNSCC patients present with locally advanced disease that requires a modern multidisciplinary approach involving surgery, radiation and pharmacotherapy. However, patients with locally advanced HNSCC frequently develop locoregional recurrence and/or distant metastasis after definitive treatment. The risk of failure is particularly high in patients with inadequate resection margins, extra-nodal spread or multiple lymph node involvement (Bonner et al., 2010) . In these high-risk patients, primary surgery is often followed by adjuvant radiation therapy. In spite of this intense treatment regimen, locoregional recurrence occurs in about 30% of patients, distant metastasis occurs in about 25% of patients and the 5-year survival rate is a dismal 40% (Laramore et al., 1992) . Thus, a critical need remains to identify and characterize genes that are responsible for promoting an aggressive HNSCC phenotype prone to relapse and metastasis to allow for better clinical management.
Protein kinase C (PKC) is a family of serine/threonine kinases known to have critical roles in the signal transduction pathways involved in proliferation, differentiation, apoptosis and migration (Dempsey et al., 2000; Jaken and Parker, 2000; Gutcher et al., 2003; Aziz et al., 2010) . Published work showed that PKCa, e and z are dysregulated in HNSCC and contribute to HNSCC development and/or progression. PKCz was reported to control epidermal-growth-factor-receptor-dependent proliferation of HNSCC cells (Cohen et al., 2006) . A recent study showed that PKCa downregulates microRNA (miR)-15a to enhance DNA synthesis and cell-cycle progression in HNSCC (Cohen et al., 2009) . Moreover, elevated PKCa expression was found to be associated with poor prognosis in HNSCC (Cohen et al., 2009) . Our laboratory demonstrated that PKCe is elevated in HNSCC and promotes an invasive and motile phenotype through modulation of RhoA and RhoC GTPases (Pan et al., 2006) . In primary HNSCC tumors, PKCa, b, e, g and z levels were shown to be elevated but only PKCe was found to be a prognostic biomarker, even better than the traditional gold standard of TNM staging (Martinez-Gimeno et al., 1995) . This prospective study indicated that elevated PKCe is significantly associated with an increase in disease recurrence and a decrease in overall survival (Martinez-Gimeno et al., 1995) .
It is clear that PKCe is elevated in HNSCC; however, the molecular mechanisms leading to increased PKCe levels remain to be elucidated. In this study, we demonstrate that miR-107 directly regulates PKCe in HNSCC. An inverse association was found for miR-107 and PKCe in HNSCC cell lines and tumor specimens. Overexpression of miR-107 decreased PKCe levels, and reduced the tumorigenic properties of HNSCC cells in vitro and in vivo. Moreover, enforced expression of miR-resistant PKCe partially reversed the loss-of-function phenotype in miR-107-overexpressing HNSCC cells. Our work revealed a novel mechanism for PKCe dysregulation in HNSCC and demonstrated miR-107 as a candidate tumor suppressor in this patient population.
Results
Inverse association between miR-107 and PKCe in HNSCC cell lines Our laboratory and others reported that PKCe is elevated in HNSCC (Martinez-Gimeno et al., 1995; Cohen et al., 2006; Pan et al., 2006) . However, the molecular mechanism of this observation remains to be elucidated. Several miRs were predicted by TargetScan to bind to the 3 0 -untranslated region (UTR) of PKCe, suggesting that miRs may be a negative regulator of PKCe. We focused our initial experiments on miR-103a and miR-107 as both miRs have three putative binding sites in the 3 0 -UTR of the PKCe gene. As shown in Figure 1 , three HNSCC cell lines, SCC15, SCC25 and CAL27, have significantly elevated PKCe protein levels and reduced miR-107 expression compared with primary keratinocytes. In contrast, the level of miR-103a, which has the same seed sequence as miR-107, was variable in the three HNSCC cell lines (Figure 1c) . Compared with primary keratinocytes, miR-103a expression was higher in SCC15, unchanged in SCC25 and lower in CAL27. These results provide evidence to demonstrate an inverse association between miR-107 and PKCe in HNSCC.
PKCe is a target of miR-107
To further provide evidence that miR-107 regulates PKCe, HNSCC cells were transiently transfected with pre-miR-control or pre-miR-107 (50 nmol/l for 48 h). Transfection with pre-miR-107 enhanced the expression of mature miR-107 by 329 ± 8-fold, 386 ± 4-fold, and 227±11-fold in SCC15, SCC25 and CAL27 cells, respectively (Po0.001). In comparison with pre-miRcontrol, delivery of pre-miR-107 resulted in a dramatic decrease in PKCe levels in SCC15, SCC25 and CAL27 cells confirming that PKCe is a target of miR-107 ( Figure 2a) . Next, we determined whether miR-107 directly binds to their predicted sites in the 3 0 -UTR of PKCe to control PKCe levels. In silico analysis with TargetScan, identified three putative miR-107 binding sites in the 3 0 -UTR of PKCe located at nucleotides 27-33 (site 1), 1517-1523 (site 2), and 1564-1570 (site 3). CAL27 cells were co-transfected with pre-miR-control or pre-miR-107 and a reporter expression vector containing wild-type or mutant 3 0 -UTR of PKCe cloned downstream of a luciferase gene (Figure 2c ). Pre-miR-107 blocked luciferase activity by 55±2% (Po0.01) in cells transfected with the full-length wild-type 3 0 -UTR of PKCe. Mutations in one of the three miR-107 sites dampened the inhibitory effect of pre-miR-107 on luciferase activity; 38±2% inhibition for mutant 1, 32 ± 4% inhibition for mutant 2 and 30 ± 3% inhibition for mutant 3. Interestingly, pre-miR-107 had no effect on luciferase activity in cells transfected with the 3 0 -UTR of PKCe containing mutations in all three miR-107 sites (Mut 1-3). Our work confirmed that miR-107 regulates PKCe through direct binding in the 3 0 -UTR of the PKCe mRNA and moreover, optimal suppression of PKCe requires occupation of all three miR-107 sites.
miR-107 reduces the tumorigenic potential of HNSCC in vitro and in vivo Our previous work demonstrated that PKCe has a critical role in promoting an aggressive phenotype in HNSCC (Pan et al., 2006) . As miR-107 was sufficient to dramatically reduce PKCe levels, the anti-cancer effects of miR-107 on HNSCC cells were assessed. As shown in Figure 3 , cell proliferation, DNA replication, colony formation and cell invasion were determined in SCC25 and CAL27 cells following treatment with pre-miRcontrol or pre-miR-107 (50 nmol/l). Cell proliferation was reduced in SCC25 cells by 20 ± 2% (Po0.01) and in CAL27 cells by 28±2% (Po0.01) following pre-miR-107 treatment. Pre-miR-107 blocked DNA replication and colony formation by 72 ± 5 and 70 ± 3% in SCC25 cells and 67±3 and 45±6% in CAL27 cells, respectively (Po0.01). Treatment with pre-miR-107 inhibited cell invasion by 93 ± 5% in SCC25 cells and 84 ± 8% in CAL27 cells (Po0.01).
Stable polyclonal miR-control or miR-107 overexpressing CAL27 cells were implanted in athymic nude mice to determine the effect of miR-107 on in vivo tumorigenicity ( Figure 4 ). In Figure 4a , CAL27/miR-107 cells had a dramatic increase in miR-107 expression compared with CAL27/miR-control cells (Po0.005). The levels of PKCe and two other confirmed miR-107 targets, hypoxia-inducible factor 1-b (HIF1-b) and cyclin-dependent kinase 6 (CDK6), were decreased in miR-107 overexpressing CAL27 cells. Interestingly, Dicer1, a confirmed miR-107 target in breast cancer, was unchanged in CAL27/miR-107 cells compared with CAL27-miR-control cells. Compared with anti-miRcontrol transfection, primary keratinocytes transfected with anti-miR-107 (PK/anti-miR-107) had lower mature miR-107 expression (70 ± 1% inhibition, Po0.001). Importantly, PK/anti-miR-107 cells demonstrated an increase in PKCe, HIF1-b and CDK6 protein levels providing further evidence that miR-107 is a key regulator of these genes ( Figure 4c ). Tumor growth was significantly reduced in the mice implanted with CAL27/miR-107 cells compared with CAL27/miRcontrol cells. Mice bearing CAL27/miR-control tumors had a mean tumor volume of 1691 ± 455 mm 3 at 6 weeks post implantation. In contrast, CAL27/miR-107 cells were less tumorigenic and had a mean tumor volume of 108±39 mm 3 (Po0.005, n ¼ 7). Moreover, mean tumor weight was significantly lowered by 93 ± 2% in CAL/ miR-107 tumors compared with CAL27/miR-control tumors (Po0.005, n ¼ 7). Importantly, PKCe protein levels were dramatically lower in tumors from CAL27/ 0 UTR and pre-miR-control or pre-miR-107. Renilla and Firefly luciferase activities were measured using the Dual-Luciferase Reporter assay system. Renilla luciferase is normalized to Firefly luciferase and data are presented as mean ± s.e.m. of four independent experiments. *P-value o0.01. miR-107, PKCe, and HNSCC J Datta et al miR-107 cells than in tumors from CAL27/miR-control cells. Taken together, these results indicate that downregulation of PKCe by miR-107 is an effective approach to suppress the tumorigenicity of HNSCC in vitro and in vivo.
miR-resistant PKCe reverses the anti-tumorigenic effects of miR-107
In addition to targeting PKCe, other groups have reported that miR-107 directly regulates HIF1-b and CDK6 (Lee et al., 2009; Yamakuchi et al., 2010; Feng et al., 2011) . To provide direct evidence that downregulation of PKCe is required for the anti-tumorigenic effects of miR-107, miR-resistant PKCe was overexpressed in miR-107 expressing SCC25 (SCC25/miR-107) cells to determine whether restoring PKCe would be sufficient to rescue the miR-107 loss-of-function phenotype. SCC25/miR-107 cells were transfected with a wild-type PKCe expression or empty vector without the 3 0 -UTR of PKCe. In Figure 5a , the SCC25/miR-107/PKCe cells had the proper genetic alterations and had elevated PKCe levels in a high miR-107 background. Empty vector-transfected SCC25/miR-107 cells had minimal effect on cell phenotype as these cells maintained their miR-107 loss-of-function defect compared with SCC25/miR-controls cells. Importantly, ectopic overexpression of PKCe partially rescues the defect of SCC25/miR-107 cells and resulted in a significant increase in cell proliferation (Po0.005), DNA replication (56±8%, Po0.005), colony formation (130 ± 18%, Po0.005) and cell invasion (392 ± 39%, Po0.005) compared with SCC25/miR-107/empty cells. These results reveal that the tumor-suppressive actions of miR-107 are, at least, partially through modulation of PKCe levels. miR-107 is reduced and inversely associated with PKCe in primary HNSCC tumors Our studies with HNSCC cell lines demonstrated an inverse association between miR-107 expression and PKCe protein levels. Next, we examined miR-107 and PKCe expression in primary tumors and matched normal adjacent epithelium from previously untreated HNSCC patients by quantitative PCR. As shown in Figure 6a , a majority (12/17) of HNSCC patients had significantly lower miR-107 expression in the tumor compared with normal tissue. A 37.5% reduction in miR-107 expression in the tumor compared with the normal tissue was demonstrated for this patient cohort (Po0.008, n ¼ 17); mean miR-107 expression was 0.005±0.0008 for the primary HNSCC tumors and 0.008 ± 0.0007 for the adjacent normal epithelium. These observations are consistent and further support our results demonstrating that miR-107 has tumor-suppressive actions in HNSCC. In this cohort, four patients were found to have significantly higher PKCe expression in their primary tumor compared with normal adjacent epithelium. All four patients with high PKCe were part of the cohort of 12 patients with reduced miR-107 expression in the tumor. We were unable to determine PKCe protein levels in this population due to insufficient and/or unavailable patient specimen. As miRs are known to regulate mRNA stability and translation, assessment of PKCe protein may reveal additional patients in the low miR-107 population with elevated PKCe levels in the tumor. Nonetheless, even with this small sample size, miR-107 expression was found to be significantly lower (73±13% reduction, Po0.01) in patients with high PKCe expression than in patients with low PKCe (Figure 6c ). Our results demonstrate that miR-107 is reduced in HNSCC tumors and is associated with elevated PKCe expression in HNSCC. miR-107, PKCe, and HNSCC J Datta et al differentiation, proliferation, migration and apoptosis (Calin and Croce, 2006; Hwang and Mendell, 2006; Datta et al., 2008; Nasser et al., 2008; Avissar et al., 2009; Croce, 2009; Liu et al., 2009) . Thus, it is not surprising that aberrant expression of certain miRs is associated with cancer development and progression, including HNSCC (Calin and Croce, 2006; Hwang and Mendell, 2006; Datta et al., 2008; Nasser et al., 2008; Avissar et al., 2009; Croce, 2009; Liu et al., 2009) . In the present study, our results revealed that miR-107 is under-expressed and functions as a tumor suppressor in HNSCC. Ectopic expression of miR-107 is sufficient to dampen the tumorigenic potential of HNSCC cells in vitro and in vivo. PKCe was confirmed as a direct target of miR-107 and had an inverse relationship with miR-107. Our study indicates that suppression of miR-107 leads to an increase in PKCe resulting in the development of HNSCC.
Consistent with our work, other groups have reported that miR-107 functions as a tumor suppressor in bladder, colon and pancreatic cancer. miR-107 was dramatically reduced in bladder carcinoma in situ compared with normal bladder (Ayala de la Pena et al., 2011). An inverse association between miR-107 and HIF1-b was demonstrated in human colon cancer specimens (Yamakuchi et al., 2010) . Overexpression of miR-107 inhibits HIF1-b levels and retards tumor growth in HCT116 colon cancer cells (Yamakuchi et al., 2010) . Enforced expression of miR-107 in pancreatic cancer cells, MiaPACA-2 and PANC-1, repressed CDK6 levels and inhibited cell proliferation (Lee et al., 2009) . In contrast, several reports have shown that miR-107 functions as an oncogene in breast and gastric cancer. Elevated miR-107 levels were associated with distant metastasis and poorer clinical outcome in the breast cancer (Martello et al., 2010) . Overexpression of miR-107 in MCF10A mammary epithelial cells promotes epithelial-to-mesenchymal transition resulting in a highly metastatic phenotype thorough modulation of Dicer1 (Martello et al., 2010) . In line with this report, knockdown of miR-107 leads to an increase in Dicer1 level, and inhibition of cell invasion and migration in the gastric cancer cells (Li et al., 2010) . Taken together, these results indicate that the biology of miR-107 is complex and highly celltype dependent. Our data showed that CDK6 and HIF1-b levels are decreased whereas Dicer1 levels were unchanged in CAL27/miR-107 cells compared with CAL27/miRcontrol cells. This indicates that miR-107 target genes are not regulated in concert and raises the possibility that other factors, including additional genetic alterations, may dictate which set of miR-107 targets is regulated in a particular cell type. Moreover, it is possible that downregulation of Dicer1 may be a prerequisite for miR-107 to function as an oncogene instead of a tumor suppressor. Expression of miRresistant PKCe was sufficient, at least partially, to rescue the loss-of-function phenotype observed for SCC25/miR-107 cells. This key observation indicates that a critical event for the tumor-suppressive actions of miR-107 in HNSCC is to negatively control the levels of PKCe.
Global miR expression analysis showed that miR-107 was significantly downregulated in HNSCC tumors compared with matched normal tissue (Wong et al., 2008) . In addition, miR expression profiling between 18 HNSCC cell lines and oral keratinocytes indicates that miR-107 is decreased at high frequency in HNSCC (Kozaki et al., 2008) . Our work showed that a majority (12/17) of HNSCC patients have reduced miR-107 expression in the primary tumor and, thus, provide additional support that loss of miR-107 is a frequent event in the development of HNSCC. In this cohort, HNSCC patients with high PKCe mRNA expression had a dramatic 73% reduction in miR-107 expression compared with patients with low PKCe mRNA expression. This observation is in line with our in vitro results and provide further evidence that miR-107 is inversely associated with PKCe in HNSCC.
In summary, our results showed that miR-107 functions as a tumor suppressor in HNSCC through regulation of PKCe. Reconstitution of miR-107 is sufficient to retard the tumorigenicity of HNSCC cells. Our study indicates that the reduction in miR-107 expression is a pathogenetic event in HNSCC and suggests that miR-107 may be a potential anti-cancer therapeutic for this patient population.
Materials and methods

Cell culture
Human HNSCC cell lines (SCC15, SCC25 and CAL27) were obtained from ATCC (Rockville, MD, USA). CAL27 cells were cultured in DMEM medium containing 10% fetal bovine serum. SCC25 and SCC15 cells were grown in DMEM/F12 (1:1) medium containing 10% fetal bovine serum. Primary keratinocytes were obtained from ATCC and cultured in EpiLife medium (Invitrogen, Carlsbad, CA, USA) supplemented with Ca 2 þ and other growth factors in a 5% CO 2 incubator at 37 1C. SCC15, SCC25 and CAL27 cell lines were authenticated using short tandem repeat profiling (ATCC).
Generation of transient and stable cell lines
Transient miR-107 and miR-control overexpressing SCC15, SCC25 and CAL27 cells were generated by transfection with pre-miR-107 or pre-miR-control (50 nmol/l) using Lipofectamine Cells were harvest after 48 h for gene expression, protein levels and functional assays. Stable CAL27/miR-107, CAL27/ miR-control, SCC25/miR-107 and SCC25/miR-control were generated by transduction using shMIMIC miR-107 or miRcontrol lentiviral particles (Thermo Fisher Scientific, Waltham, MA, USA). Cells were incubated with viral particles (multiplicity of infection ¼ 1:20) mixed with polybrene (at a final concentration of 10 mg/ml) for 12 h. Subsequently, cells were cultured in complete growth media for 72 h and polyclonal populations were selected with 1 mg/ml puromycin. SCC25/ miR-107 cells were transiently transfected with an empty vector or a PKCe expression vector (Ex-A1280-MO2; GeneCopoeia, Rockville, MD, USA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Cells were harvested after 48 h for protein levels and functional assays. Primary keratinocytes were transiently transfected with anti-miRcontrol or anti-miR-107 (100 nmol/l) using Lipofectamine 2000. Cells were harvested after 48 h for gene expression and protein levels.
Real-time PCR
Total RNA was isolated from HNSCC cells and primary keratinocytes with TRIzol (Invitrogen). Expression of PKCe, GAPDH, mature miR-103a, mature miR-107 and RNU44 were determined using the Applied Biosystems 7900HT Fast Real-Time PCR System with validated TaqMan gene expression assays (Applied Biosystems, Foster City, CA, USA). PKCe expression was normalized to GAPDH, and mature miR-103a/miR-107 expression was normalized to RNU44 using the DDCt method.
Luciferase reporter assay
Wild-type or mutant PKCe-3 0 UTR psiCHECK-2 plasmid was transiently transfected into H293T cells. Cells were transfected with 50 ng of psiCHECK-2 along with pre-miR-107 or premiR-control (100 nmol/l) using Lipofectamine 2000 (Invitrogen). After 48 h, cells were washed with phosphate buffered saline, resuspended in the lysis buffer (100 mM potassium phosphate pH 7.8, 0.2% Triton X-100, 0.5 mM dithiothreitol) and measured for Firefly/Renilla luciferase activities in a luminometer using the Dual-Light System (Applied Biosystems). Renilla luciferase activities were normalized to Firefly luciferase activities to control for transfection efficiency.
Western blot analysis
Whole-cell lysates were mixed with Laemmli loading buffer, boiled, separated by SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. Subsequently, immunoblot analyses were performed using antibodies specific to PKCe (Santa Cruz Biotechnology, Santa Cruz, CA, USA), CDK6 (Thermo Fisher Scientific), HIF1-b (Cell Signaling Technology, Danvers, MA, USA), Dicer1 (Abcam, Cambridge, MA, USA) or tubulin (Cell Signaling Technology). The signal was developed with ECL (Thermo Fisher Scientific) after incubation with appropriate secondary antibodies.
Cell invasion and proliferation
Cell invasion was determined as described from the cell invasion assay kit (BD Biosciences, Bedford, MA, USA). Cells were harvested and resuspended in serum-free medium. An aliquot (1 Â 10 5 cells) of the prepared cell suspension was added into the chamber and incubated for 24 h at 37 1C in a 10% CO 2 tissue culture incubator. Non-invading cells were gently removed from the interior of the inserts with a cottontipped swab. Invasive cells were stained and counted. Cell proliferation was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reagent to detect metabolic active cells (Roche Molecular Biochemicals, Nutley, NJ, USA). Absorbance was measured at 570 nm in the Spectra Max 190 ELISA reader (Molecular Devices, Sunnyvale, CA, USA) after overnight incubation.
Colony formation
Cells (500) were plated in complete growth media and allowed to grow until visible colonies formed (10-12 days). Cell colonies were fixed with cold methanol, stained with 0.25% crystal violet in 25% methanol, washed and air dried.
DNA replication
Cells (10 000 cells per well) were plated in 24-well plates and allowed to grow for 24 h. Subsequently, cells were incubated with serum-free media for 16 h and then incubated with complete growth media containing 1 mCi of
